Union for International Cancer Control (UICC) shared a post on LinkedIn:
“Celebrating a milestone in access to cancer medicines.
Around 375 people living with chronic myeloid leukaemia (CML) in El Salvador, Indonesia, and the Philippines have received quality-assured generic nilotinib – a vital treatment included in the World Health Organization’s Model List of Essential Medicines.
This progress was made possible through the ATOM Coalition, led by UICC, which facilitated an agreement in 2022 by Novartis to grant a public health-oriented voluntary license for nilotinib to the Medicines Patent Pool (MPP), also a Coalition partner.
This was the first license of its kind for a cancer medicine, paving the way for multiple generic manufacturers to supply quality-assured nilotinib across LMICs – a powerful example of how partnerships can expand access to life-saving cancer treatment.”
More posts featuring UICC.